Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23120254 | 0.83 | ALDH1A1 (0.81) | MAPTNPC1LMNAALDH1A1GSK3B | |
| SCHEMBL19714443 | 0.82 | LMNA (0.60) | MAPTLMNAALDH1A1CYP2C19MPO | |
| SCHEMBL12497263 | 0.78 | LMNA (0.69) | LMNAGSK3BCYP2C19TSHRHTT | |
| SCHEMBL12495433 | 0.78 | ALDH1A1 (0.72) | MAPTNPC1LMNAALDH1A1GSK3B | |
| SCHEMBL20715449 | 0.78 | KMT2A (0.76) | MAPTNPC1LMNAALDH1A1GSK3B | |
| SCHEMBL27858704 | 0.77 | MMP2 (0.73) | LMNAGSK3BCYP2C19TSHRHTT | |
| SCHEMBL31134161 | 0.76 | PIN1 (0.65) | MAPTNPC1ALDH1A1TSHRHTT | |
| SCHEMBL11400323 | 0.76 | KDM4E (0.62) | MAPTLMNAALDH1A1GSK3BCYP2C19 | |
| SCHEMBL2607501 | 0.76 | GSK3B (0.69) | MAPTLMNAALDH1A1GSK3BCYP2C19 | |
| SCHEMBL17824289 | 0.76 | LMNA (0.66) | LMNAGSK3BCYP2C19TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-12-03 | — | — | US | disclosed |
| WO-2019028308-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | AZI2, ATP6V1B1, GLS | MAPT 4542/4885NPC1 2132/4885LMNA 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.